Cytovance Biologics

Cytovance Biologics

Biotechnology Research

Oklahoma City, OK 6,984 followers

We are Cytovance Biologics, your responsive, reliable, and resourceful CDMO Partner.

About us

Welcome to Cytovance Biologics! Born from a decades-long history in drug development, we believe in creating a healthier world where every biologic’s path to commercialization is advanced by a CDMO partner that delivers ingenuity end-to-end. Whether your large molecule product needs the flexibility of a customized approach or the efficiency of a predetermined platform process, Team Cytovance has the deep expertise in microbial and mammalian expression systems to support your scale-up at every stage. From early needs like cell line development and strain selection to cGMP manufacturing for clinical and commercial production, our team is your team. Together, we will guide your asset through the complexities of manufacturing and deliver it to its next milestone. With a 95% scale-up success rate and quality, scalability, and reproducibility top of mind, we bring a range of therapeutic proteins and antibodies to the clinic, including: ● Biosimilars ● Cytokines ● Enzymes/Hormones ● Fusion Proteins ● Bispecific, Fragment, and Monoclonal Antibodies ● Recombinant Protein ● Vaccines ● And More We are the Responsible, Reliable, and Resourceful partner you and your product deserve.

Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Oklahoma City, OK
Type
Privately Held
Founded
2003
Specialties
Process Development, Cell Line Development, Cell Culture, Cell Banking, cGMP Manufacturing, Analytical Development Support, QC Microbiology Services, Mammalian Cell Culture, Microbial Fermentation, R&D Service, Protein Expression Technology, Analytical Services, Stability Testing, Regulatory Support, Program Management, Quality Assurance, Process Validation, and Tech Transfer

Locations

Employees at Cytovance Biologics

Updates

Similar pages

Funding

Cytovance Biologics 2 total rounds

Last Round

Debt financing

US$ 20.0M

See more info on crunchbase